Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Shubham Pant, Erika Hamilton, Susanna V Ulahannan, James F Strauss, Fadi S Braiteh, Mo Huang, Danny Chih Hsun Liaw
BACKGROUND: In this first-in-human phase 1b study (ClinicalTrials.gov identifier NCT02761694) of advanced solid tumors with PIK3CA/AKT/PTEN mutations, the authors investigated the safety and efficacy of the pan-AKT inhibitor vevorisertib (MK-4440; ARQ 751) as monotherapy or with paclitaxel or fulvestrant. METHODS: Patients with histologically confirmed, advanced or recurrent, PIK3CA/AKT/PTEN-mutated solid tumors, measurable disease according to Response Evaluation Criteria in Solid Tumors, version 1...
March 27, 2023: Cancer
#2
JOURNAL ARTICLE
Cristiane Decat Bergerot, Paulo Gustavo Bergerot, Marianne Razavi, Errol J Philip, Sabri Lakhdari, Marcos Vinicius da Silva França, Lorena Nascimento Manrique Molina, Alici Natalia de Sousa Freitas, Mariane Cunha Taveira, Andressa Cardoso de Azeredo, William Hiromi Fuzita, Cristiano Menezes Fernandes, Raquel Batista Pio, Romildo de Araujo, Milena Macedo Couto, Vitor Fiorin de Vasconcellos, Maria Fernanda Nonino, David Lee, João Nunes de Matos Neto, Marco Murilo Buso, Enrique Soto-Perez-de-Celis, William Dale
BACKGROUND: This study sought to determine the feasibility and acceptability of a remote geriatric assessment (GA) and implementation (GAIN) program in Brazil. The authors also explored the effect of this program on health-related quality of life (HR-QOL) outcomes 3 months after initiating treatment. METHODS: This is a longitudinal study enrolling older adults (65+ years), diagnosed with any type of solid tumor, scheduled to initiate chemotherapy in a networked Brazilian cancer center...
March 25, 2023: Cancer
#3
JOURNAL ARTICLE
Beryl L Manning-Geist, Ryan M Kahn, David Nemirovsky, Jeffrey Girshman, Anya Laibangyang, Sushmita Gordhandas, Alexia Iasonos, M Herman Chui, Kara Long Roche, Oliver Zivanovic, Dennis S Chi, Carol Aghajanian, Rachel N Grisham
BACKGROUND: Data on platinum sensitivity of low-grade serous ovarian carcinoma (LGSOC) in the upfront setting is lacking, and there is limited and contradictory information on chemotherapy responses in recurrent disease. METHODS: Patients with LGSOC seen at a comprehensive cancer center from January 1, 1998 to September 30, 2021 were identified from institutional databases. Response to neoadjuvant chemotherapy (NACT) or adjuvant platinum-based chemotherapy and to second- to fifth-line regimens was retrospectively characterized by Response Evaluation Criteria in Solid Tumors (RECIST) v1...
March 23, 2023: Cancer
#4
JOURNAL ARTICLE
Ying-Ying Ma, Ze-Liang Wei, Ya-Jing Xu, Ji-Min Shi, Hai Yi, Yong-Rong Lai, Er-Lie Jiang, San-Bin Wang, Tao Wu, Lei Gao, Li Gao, Pei-Yan Kong, Qin Wen, Hai Bai, Yu Li, Yi-Geng Cao, Qiao-Chuan Li, Zhong-Ming Zhang, Bei-Cai Liu, Yi Su, Xiao-Yu Lai, Xia Ma, Ting-Ting Cheng, Yi Luo, Xi Zhang, Cheng Zhang
BACKGROUND: Minimal residual disease (MRD) is an important prognostic factor for survival in adults with acute leukemia. The role of pretransplantation MRD status in myelodysplastic syndrome with excess blasts (MDS-EB) is unknown. This study retrospectively analyzed the relationship between pretransplantation MRD status and long-term survival. MATERIALS AND METHODS: Patients with MDS-EB who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) from March 5, 2005, to November 8, 2020, were included...
March 23, 2023: Cancer
#5
JOURNAL ARTICLE
Anna Weiss, Olga Martínez-Sáez, Adrienne G Waks, Alison Laws, Monica McGrath, Paolo Tarantino, Leah Portnow, Eric Winer, María Rey, Marta Tapia, Aleix Prat, Ann H Partridge, Sara M Tolaney, Juan M Cejalvo, Elizabeth A Mittendorf, Tari A King
BACKGROUND: The optimal treatment strategy for patients with small human epidermal growth factor receptor 2 (HER2)-positive tumors is based on nodal status. The authors' objective was to evaluate pathologic nodal disease (pathologic lymph node-positive [pN-positive] and pathologic lymph node-positive after preoperative systemic therapy [ypN-positive]) rates in patients who had clinical T1-T2 (cT1-cT2)N0M0, HER2-positive breast cancer treated with upfront surgery or neoadjuvant chemotherapy (NAC)...
March 23, 2023: Cancer
#6
JOURNAL ARTICLE
Shaked Lev-Ari, Michael Serzan, Tianmin Wu, Andrew Ip, Lauren Pascual, Brittany Sinclaire, Shari Adams, Michael Marafelias, Lakshmi Ayyagari, Sarvarinder K Gill, Barbara Ma, Jacob P Zaemes, Alexandra Della Pia, Adil Alaoui, Subha Madhavan, Anas Belouali, Andrew Pecora, Jaeil Ahn, Michael B Atkins, Neil J Shah
BACKGROUND: Immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs) are often managed via immunosuppressive agents (ISAs); however, their impact on ICI efficacy is not well studied. The impact of the use of ISAs on ICI efficacy in patients with advanced melanoma was therefore investigated. METHODS: This is a real-world, multicenter, retrospective cohort study of patients with advanced melanoma who received ICIs (n = 370)...
March 23, 2023: Cancer
#7
JOURNAL ARTICLE
Aakash Desai, Neha K Reddy, Vivek Subbiah
The advent of precision medicine has changed the landscape of oncologic biomarkers, drug discovery, drug development, and, more importantly, outcomes for patients with cancer. Precision oncology entails the genomic profiling of tumors to detect actionable aberrations. The advances in clinical next-generation sequencing from both tumor tissue and liquid biopsy and availability of targeted therapies has rapidly entered mainstream clinical practice. In this review, recent major developments in precision oncology that have affected outcomes for patients with cancer are discussed...
March 22, 2023: Cancer
#8
JOURNAL ARTICLE
Jordan Kharofa, David Haslam, Rachael Wilkinson, Allison Weiss, Sameer Patel, Kyle Wang, Hope Esslinger, Olugbenga Olowokure, Davendra Sohal, Greg Wilson, Syed Ahmad, Senu Apewokin
BACKGROUND: The 5-year overall survival of pancreas adenocarcinoma (PCa) remains less than 10%. Clinical and tumor genomic characteristics have not differentiated PCa long-term survivors (LTSs) from unselected patients. Preclinical studies using fecal transplant experiments from LTSs of PCa have revealed delayed tumor growth through unknown mechanisms involving the fecal microbiota. However, features of the fecal microbiome in patients with long-term survival are not well described. METHODS: In this cross-sectional study, comprehensive shotgun metagenomics was performed on stool from PCa patients with long-term survival (n = 16)...
March 21, 2023: Cancer
#9
JOURNAL ARTICLE
Andrew G Hudnut, Earl Hubbell, Oliver Venn, Timothy R Church
BACKGROUND: Positive results of a multi-cancer early detection (MCED) test require confirmatory diagnostic workup. Here, residual current cancer risk (RR) during the process of diagnostic resolution, including situations where the initial confirmatory test does not provide resolution, was modeled. METHODS: A decision-tree framework was used to model conditional risk in a patient's journey through confirmatory diagnostic options and outcomes. The diagnostic journey assumed that cancer signal detection (a positive MCED test result) had already led to a transition from screening to diagnosis and began with an initial positive predictive value (PPV) from the positive result...
March 21, 2023: Cancer
#10
JOURNAL ARTICLE
Georgios E Christakopoulos, Kendra N Walker, Jesse Smith, Clifford M Takemoto, Yan Zheng, Ching-Hon Pui, Raul C Ribeiro, Lei Wang, Stanley B Pounds, Jeffrey E Rubnitz, Hiroto Inaba
BACKGROUND: Hyperleukocytosis in patients with acute myeloid leukemia (AML) has been associated with worse outcomes. For cytoreduction, leukapheresis has been used but its clinical utility is unknown, and low-dose cytarabine (LD-cytarabine) is used as an alternative method. METHODS: Children with newly diagnosed AML treated between 1997 and 2017 in institutional protocols were studied. Hyperleukocytosis was defined as a leukocyte count of ≥100 × 109 /L at diagnosis...
March 21, 2023: Cancer
#11
EDITORIAL
Larry Kessler, Michelle M Le Beau, Robert A Smith, Fiona M Walter, Richard Wender
No abstract text is available yet for this article.
March 21, 2023: Cancer
#12
JOURNAL ARTICLE
Honghong Zhang, Yang Wan, Hongsheng Wang, Jiaoyang Cai, Jie Yu, Shaoyan Hu, Yongjun Fang, Ju Gao, Hua Jiang, Minghua Yang, Changda Liang, Runming Jin, Xin Tian, Xiuli Ju, Qun Hu, Hui Jiang, Zhifan Li, Ningling Wang, Lirong Sun, Alex W K Leung, Xuedong Wu, Xiaowen Qian, Maoxiang Qian, Chi-Kong Li, Jun Yang, Jingyan Tang, Xiaofan Zhu, Shuhong Shen, Li Zhang, Ching-Hon Pui, Xiaowen Zhai
BACKGROUND: Contemporary risk-directed treatment has improved the outcome of patients with acute lymphoblastic leukemia (ALL) and TCF3::PBX1 fusion. In this study, the authors seek to identify prognostic factors that can be used to further improve outcome. METHODS: The authors studied 384 patients with this genotype treated on Chinese Children's Cancer Group ALL-2015 protocol between January 1, 2015 and December 31, 2019. All patients provisionally received intensified chemotherapy in the intermediate-risk arm without prophylactic cranial irradiation; those with high minimal residual disease (MRD) ≥1% at day 46 (end) of remission induction were candidates for hematopoietic cell transplantation...
March 21, 2023: Cancer
#13
JOURNAL ARTICLE
Rachel Tillery Webster, Rikeenkumar Dhaduk, Mallorie L Gordon, Robyn E Partin, Alicia S Kunin-Batson, Tara M Brinkman, Victoria W Willard, Jennifer M Allen, Nicole M Alberts, Jennifer Q Lanctot, Matthew J Ehrhardt, Zhenghong Li, Melissa M Hudson, Leslie L Robison, Kirsten K Ness
BACKGROUND: There is limited understanding of associations between a combination of health behaviors (physical activity, sedentary/screen-time, diet) and cardiometabolic health risk factors, physical performance, and emotional health among young (<18) childhood cancer survivors (CCS). The aims of this research were to address this gap by 1) deriving health behavior adherence profiles among CCS, and 2) examining associations among demographic, diagnosis and/or treatment exposures, cardiometabolic, physical performance, and emotional functioning with health behavior profile membership...
March 21, 2023: Cancer
#14
JOURNAL ARTICLE
Ghassan K Abou-Alfa, Xiaoliang Wang, Christina M Parrinello, Anala Gossai, Richard Kim, Kelly Magee, Rebecca A Miksad
BACKGROUND: Clinical trials suggest α-fetoprotein (AFP) reduction may be prognostic among patients with advanced hepatocellular carcinoma. However, the association of AFP reduction with outcomes in real-world settings is unclear. METHODS: Patients with advanced hepatocellular carcinoma between January 1, 2011, and June 30, 2021, first-line tyrosine kinase inhibitor, and baseline and posttreatment AFP values (closest to 8 ± 2 weeks after first-line initiation) were included...
March 21, 2023: Cancer
#15
JOURNAL ARTICLE
Jeanne S Mandelblatt, Julie J Ruterbusch, Hayley S Thompson, Xingtao Zhou, Traci N Bethea, Lucile Adams-Campbell, Kristen Purrington, Ann G Schwartz
BACKGROUND: Discrimination can adversely affect health and accelerate aging, but little is known about these relationships in cancer survivors. This study examines associations of discrimination and aging among self-identified African American survivors. METHODS: A population-based sample of 2232 survivors 20-79 years old at diagnosis were enrolled within 5 years of breast (n = 787), colorectal (n = 227), lung (n = 223), or prostate (n = 995) cancer between 2017 and 2022...
March 20, 2023: Cancer
#16
EDITORIAL
Joseph F Kearney, Deborah Weighill, Jen Jen Yeh
No abstract text is available yet for this article.
March 18, 2023: Cancer
#17
JOURNAL ARTICLE
Hiroshi Ohyama, Yosuke Hirotsu, Kenji Amemiya, Yoshifumi Miura, Sumio Hirose, Toshio Oyama, Yuji Iimuro, Yuichiro Kojima, Rintaro Mikata, Hitoshi Mochizuki, Naoya Kato, Masao Omata
BACKGROUND: Obtaining sufficient pancreaticobiliary tumor tissue for genomic profiling has limitations. Liquid biopsies using plasma do not provide sufficient sensitivity. Thus, this study aimed to determine the effectiveness of liquid biopsy between bile and plasma for identifying oncogenic and drug-matched mutations. METHODS: This study created a panel of 60 significantly mutated genes specific to pancreaticobiliary cancer (PBCA) and used it for genomic analysis of 212 deoxyribonucleic acid (DNA) samples (87 bile supernatant, 87 bile precipitate, and 38 plasma) from 87 patients with PBCA...
March 18, 2023: Cancer
#18
JOURNAL ARTICLE
Francesca Palandri, Massimo Breccia, Camilla Mazzoni, Giuseppe Auteri, Elena Maria Elli, Malgorzata M Trawinska, Nicola Polverelli, Mario Tiribelli, Giulia Benevolo, Alessandra Iurlo, Alessia Tieghi, Florian H Heidel, Giovanni Caocci, Eloise Beggiato, Gianni Binotto, Francesco Cavazzini, Maurizio Miglino, Costanza Bosi, Monica Crugnola, Monica Bocchia, Bruno Martino, Novella Pugliese, Mattia Biondo, Marta Venturi, Luigi Scaffidi, Alessandro Isidori, Daniele Cattaneo, Mauro Krampera, Fabrizio Pane, Daniela Cilloni, Gianpietro Semenzato, Roberto M Lemoli, Antonio Cuneo, Elisabetta Abruzzese, Daniela Bartoletti, Simona Paglia, Nicola Vianelli, Michele Cavo, Massimiliano Bonifacio, Giuseppe A Palumbo
BACKGROUND: Patients with cytopenic myelofibrosis (MF) have more limited therapeutic options and poorer prognoses compared with patients with the myeloproliferative phenotype. AIMS AND METHODS: Prognostic correlates of cytopenic phenotype were explored in 886 ruxolitinib-treated patients with primary/secondary MF (PMF/SMF) included in the RUX-MF retrospective study. Cytopenia was defined as: leukocyte count <4 × 109 /L and/or hemoglobin <11/<10 g/dL (males/females) and/or platelets <100 × 109 /L...
March 18, 2023: Cancer
#19
JOURNAL ARTICLE
Katherine I Foster, Kenna R M Shaw, Jeff Jin, Shannon N Westin, Timothy A Yap, Deanna M Glassman, Amir A Jazaeri, Jose A Rauh-Hain, Sanghoon Lee, Bryan M Fellman, Zhenlin Ju, Yuexin Liu, Nicole D Fleming, Anil K Sood
BACKGROUND: Tumor-based next-generation sequencing is used inconsistently as a tool to tailor treatment of ovarian cancer, yet beyond detection of somatic BRCA1 and BRCA2 mutations, the clinical benefit is not well established. This study aimed to assess the clinical relevance of tumor-based next-generation sequencing (tbNGS) in patients with ovarian cancer. METHODS: This retrospective study included patients with high-grade epithelial ovarian carcinoma. tbNGS results were identified in the electronic medical record using optical character recognition and natural language processing...
March 17, 2023: Cancer
#20
JOURNAL ARTICLE
Ellen D'Hooghe, Rhoikos Furtwängler, Tanzina Chowdhury, Christian Vokuhl, Reem Al-Saadi, Kathy Pritchard-Jones, Norbert Graf, Gordan M Vujanić
BACKGROUND: Patients treated with preoperative chemotherapy with stage I intermediate-risk Wilms tumor (IR-WT) represent the largest group of patients with Wilms tumor (WT), and they have excellent outcomes. METHODS: The authors performed a retrospective analysis of patients with stage I epithelial (ET-WT) or stromal type WT (ST-WT) treated pre- and postoperatively according to the International Society of Paediatric Oncology-WT-2001 protocol in the UK Children's Cancer and Leukaemia Group and Gesellschaft für Pädiatrische Onkologie und Hämatologie groups' participation in the relevant WT trials and studies (2001-2020)...
March 17, 2023: Cancer
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
